Response of conventional chondrosarcoma to gemcitabine alone: a case report

详细信息    查看全文

• 作者：Salvatore Provenzano (1)
  Nadia Hindi (1)
  Carlo Morosi (2)
  Mara Ghilardi (3)
  Paola Collini (4)
  Paolo G Casali (1)
  Silvia Stacchiotti (1)
  
  1. Adult mesenchymal tumour & Rare cancer Medical Oncology Unit ; Cancer Medicine Department ; Fondazione IRCCS Istituto Nazionale Tumori ; via G. Venezian ; 1 I-20133 ; Milan ; Italy
  2. Department of Radiology ; Fondazione IRCCS Istituto Nazionale Tumori ; Milan ; Italy
  3. Medical Oncology Unit ; Ospedale di Treviglio ; Azienda Ospedaliera Treviglio ; Treviglio ; (BG) ; Italy
  4. Department of Diagnostic Pathology and Laboratory Medicine ; Fondazione IRCCS Istituto Nazionale Tumori ; Milan ; Italy
  
• 关键词：Sarcoma ; Bone sarcoma ; Chondrosarcoma ; Gemcitabine ; Chemotherapy
• 刊名：Clinical Sarcoma Research
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：5
• 期：1
• 全文大小：2,651 KB
• 参考文献：1. Fletcher, CDM, Bridge, JA, Hogendoorn, PCW, Mertens, F (2013) WHO Classification of Tumours of Soft Tissue and Bone. IARC, Lyon
  2. Bj枚rnsson, J, McLeod, RA, Unni, KK, Ilstrup, DM, Pritchard, DJ (1998) Primary chondrosarcoma of long bones and limb girdles. Cancer 83: pp. 2105-19 3:10<2105::AID-CNCR9>3.0.CO;2-U" target="_blank" title="It opens in new window">CrossRef
  3. Angelini, A, Guerra, G, Mavrogenis, AF, Pala, E, Picci, P, Ruggieri, P (2012) Clinical outcome of central conventional chondrosarcoma. J Surg Oncol 106: pp. 929-37 3173" target="_blank" title="It opens in new window">CrossRef
  4. Evans, HL, Ayala, AG, Romsdahl, MM (1977) Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 40: pp. 818-31 34>3.0.CO;2-B" target="_blank" title="It opens in new window">CrossRef
  5. Uhl, M, Mattke, M, Welzel, T, Oelmann, J, Habl, G, Jensen, AD (2014) High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. Cancer 120: pp. 1579-85 CrossRef
  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25: pp. 113-23 3/annonc/mdu256" target="_blank" title="It opens in new window">CrossRef
  6. Italiano, A, Mir, O, Cioffi, A, Palmerini, E, Piperno-Neumann, S, Perrin, C (2013) Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol 24: pp. 2916-22 3/annonc/mdt374" target="_blank" title="It opens in new window">CrossRef
  7. Fox, E, Patel, S, Wathen, JK, Schuetze, S, Chawla, S, Harmon, D (2012) Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist 17: pp. 321 34/theoncologist.2010-0265" target="_blank" title="It opens in new window">CrossRef
  8. Frezza, AM, Cesari, M, Baumhoer, D, Biau, D, Bielack, S, Campanacci, DA (2015) Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur J Cancer 51: pp. 374-81 CrossRef
  9. Maldegem, AM, Bov茅e, JV, Gelderblom, H (2014) Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clin Sarcoma Res 4: pp. 11 3329-4-11" target="_blank" title="It opens in new window">CrossRef
  10. Rocca, RV, Morgan, KW, Paris, K, Baeker, TR (1999) Recurrent chondrosarcoma of the cranial base: a durable response to ifosfamide-doxorubicin chemotherapy. J Neurooncol 41: pp. 281-3 3/A:1006154904014" target="_blank" title="It opens in new window">CrossRef
  11. Nooij, MA, Whelan, J, Bramwell, VHC, Taminiau, AT, Cannon, S, Hogendoorn, PCW (2005) Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study. Eur J Cancer 41: pp. 225-30 CrossRef
  12. Maldegem, AM, Gelderblom, H, Palmerini, E, Dijkstra, SD, Gambarotti, M, Ruggieri, P (2014) Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer 120: pp. 3159-64 CrossRef
  13. Italiano, A, Cesne, A, Bellera, C, Piperno-Neumann, S, Duffaud, F, Penel, N (2013) GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol 24: pp. 2922-6 3/annonc/mdt391" target="_blank" title="It opens in new window">CrossRef
  14. Lund, B, Kristjansen, PE, Hansen, HH (1993) Clinical and preclinical activity of 2鈥?2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19: pp. 45-55 305-7372(93)90026-N" target="_blank" title="It opens in new window">CrossRef
  15. Stacchiotti, S, Palassini, E, Sanfilippo, R, Vincenzi, B, Arena, MG, Bochicchio, AM (2012) Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann Oncol 23: pp. 501-8 3/annonc/mdr066" target="_blank" title="It opens in new window">CrossRef
  16. Maki, RG, Wathen, JK, Patel, SR, Priebat, DA, Okuno, SH, Samuels, B (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 25: pp. 2755-63 CrossRef
  17. Hensley, ML, Maki, R, Venkatraman, E, Geller, G, Lovegren, M, Aghajanian, C (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: pp. 2824-31 CrossRef
  18. Pautier, P, Floquet, A, Penel, N, Piperno-Neumann, S, Isambert, N, Rey, A (2012) Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group. Oncologist 17: pp. 1213-20 34/theoncologist.2011-0467" target="_blank" title="It opens in new window">CrossRef
  19. Lee, EM, Rha, SY, Lee, J, Park, KH, Ahn, J-H (2012) Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Cancer Chemother Pharmacol 69: pp. 635-42 CrossRef
  20. Navid, F, Willert, JR, McCarville, MB, Furman, W, Watkins, A, Roberts, W (2008) Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 113: pp. 419-25 3586" target="_blank" title="It opens in new window">CrossRef
  21. Bov茅e, JVMG, Hogendoorn, PCW, Wunder, JS, Alman, B (2010) Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 10: pp. 481-8 38/nrc2869" target="_blank" title="It opens in new window">CrossRef
  22. Andrea, CE, Reijnders, CMA, Kroon, HM, Jong, D, Hogendoorn, PCW, Szuhai, K (2012) Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT. Oncogene 31: pp. 1095-104 38/onc.2011.311" target="_blank" title="It opens in new window">CrossRef
  23. Gelderblom, H, Hogendoorn, PCW, Dijkstra, SD, Rijswijk, CS (2008) The clinical approach towards chondrosarcoma. Oncologist 13: pp. 320-9 34/theoncologist.2007-0237" target="_blank" title="It opens in new window">CrossRef
  24. Merimsky, O, Meller, I, Flusser, G, Kollender, Y, Issakov, J, Weil-Ben-Arush, M (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol 45: pp. 177-81 CrossRef
  
• 刊物主题：Cancer Research; Oncology; Surgical Oncology;
• 出版者：BioMed Central
• ISSN：2045-3329

文摘

Conventional skeletal chondrosarcoma is a bone neoplasm, which is poorly sensitive to anthracyclines-based chemotherapy. We report on an 18-month-long tumour response to gemcitabine as single agent in a young patient with an advanced secondary peripheral conventional chondrosarcoma, previously treated unsuccessfully with anthracyclines, ifosfamide, platinum, etoposide.